Desmoplakin-Specific ARVC Risk Scores: Deep Phenotyping to Drive Precision Medicine

Affiliations

Editorial

Graham H Bevan et al. JACC Adv. 2024.

. 2024 Feb 1;3(3):100833.

doi: 10.1016/j.jacadv.2024.100833. eCollection 2024 Mar.

No abstract available

Keywords: ARVC; arrhythmogenic cardiomyopathy; cardiomyopathy; sudden cardiac death.

Conflict of interest statement

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

1. Marcus F.I., Fontaine G.H., Guiraudon G., et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation. 1982;65:384–398. - PubMed
1. Asatryan B., Asimaki A., Landstrom A.P., et al. Inflammation and immune response in arrhythmogenic cardiomyopathy: state-of-the-art review. Circulation. 2021;144:1646–1655. - PMC - PubMed
1. Corrado D., Basso C., Judge D.P. Arrhythmogenic cardiomyopathy. Circ Res. 2017;121:784–802. - PubMed
1. Gasperetti A., Carrick R., Protonotarios A., et al. Long-term arrhythmic follow-up and risk stratification of patients with desmoplakin-associated arrhythmogenic right ventricular cardiomyopathy. JACC: Adv. 2024;3:100832.
1. Marcus F.I., McKenna W.J., Sherrill D., et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2010;121:1533–1541. - PMC - PubMed